Trial intelligence / Profile preview

Phase 2b placebo-controlled trial of NNC0109-0012 in methotrexate-inadequate responder rheumatoid arthritis

2012-000610-11Phase 2Completed

Sponsor
Novo Nordisk
Start
Jun 2012
Modality
Monoclonal Antibodies → Antibody-Based Therapeutics
Countries
1
01

Overview

Phase 2, randomised, double-blind trial of fletikumab in rheumatoid arthritis (RA) (3 arms), sponsored by Novo Nordisk. Primary endpoint: ACR20 responder rate. Started Jun 2012; status: completed.

02

Drugs

fletikumab
03

Conditions

rheumatoid arthritis (RA)

Beyond the preview

Go deeper on 2012-000610-11.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on 2012-000610-11.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call